Aims To perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk insulin-resistant women taking metformin prior to, or during pregnancy.
Introduction
Pre-eclampsia is a complication of pregnancy that occurs in the second half of gestation. It is defined as the new onset, after 20 weeks' gestation, of hypertension (≥140/90 mmHg) and proteinuria (≥300 mg per 24 h) or, in the absence of proteinuria, any of the following: thrombocytopenia (platelets <100 000/ll); impaired liver function; progressive renal insufficiency; pulmonary oedema; or cerebral or visual disturbances [1] . Pre-eclampsia is classified according to gestational age at onset: term pre-eclampsia (onset ≥37 weeks); preterm preeclampsia (34-37 weeks); and early-onset pre-eclampsia (<34 weeks) [2] . Severe features of pre-eclampsia include blood pressure ≥160/110 mmHg, thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary oedema, and cerebral or visual disturbances [1] . Pre-eclampsia is the leading cause of maternal and foetal morbidity and mortality; by conservative estimates, it affects 10 million pregnant women worldwide annually, and is responsible for 76 000 maternal and 500 000 infant deaths [3] . In addition to the short-term risks, pre-eclampsia is associated, later in life, with cardiovascular disease and/or Type 2 diabetes mellitus in both mothers and offspring [4, 5] .
The incidence of pre-eclampsia is~4-6% in the general population, but is greatly increased by insulin-resistant disorders such as gestational diabetes mellitus (GDM), Type 2 diabetes, polycystic ovary syndrome (PCOS) and obesity [6] [7] [8] . In women with pre-gestational diabetes, whether Type 1 or Type 2, the risk of pre-eclampsia is increased approximately four-fold [9, 10] .
There are currently no reliable biomarkers or effective preventative measures, and no treatments for pre-eclampsia other than delivery. The pathogenesis of pre-eclampsia is linked to aberrant angiogenesis and inadequate remodelling of the spiral uterine artery, later leading to the development of an ischaemic placenta; however, understanding of underlying mechanisms is inadequate, impeding the rationale for development of preventative and treatment strategies.
A few therapeutic approaches have been explored. Lowdose aspirin (75 mg daily) may reduce the incidence of preeclampsia by up to 25% if taken before 16 weeks' gestation [11] , and is recommended from 12 weeks' gestation for women who have one or more of the following risk factors: history of pre-eclampsia; multifoetal gestation; chronic hypertension; diabetes (Type 1 or Type 2); renal disease; or autoimmune disease (e.g. systemic lupus erythematous, antiphospholipid syndrome). Anti-oxidant supplements have also been assessed, but have so far failed to show benefit in the prevention of pre-eclampsia [10] .
Metformin can be safely used in pregnancy [12] , enabling investigation of its effects on pregnancy outcomes in women who are at higher risk, such as obese women or women with GDM, Type 2 diabetes or PCOS [13] [14] [15] [16] . Metformin reduces insulin resistance, and mitigates endothelial dysfunction and hyperglycaemia, factors that have been associated with preeclampsia [17, 18] . Metformin is an AMPK activator, and reduced AMPK pathway activity has also been implicated in the pathogenesis of pre-eclampsia [19, 20] . It is established that the circulating anti-angiogenic factor, fms-like tyrosine kinase 1 (sFlt-1) is significantly increased in pregnancies complicated by pre-eclampsia, and recently, it was shown that metformin can reduce sFlt-1 secretion from placental tissue and placental explants [21] . Metformin therefore warrants investigation as a preventive treatment for preeclampsia.
The aim of the present systematic review and meta-analysis was to evaluate evidence concerning the efficacy of metformin compared with placebo/control or insulin in reducing the incidence of pre-eclampsia in high-risk pregnant women using randomized controlled trials (RCTs) and prospective observational cohort studies.
Methods

Data sources and searches
A systematic literature search was conducted using Medline (1946) , Embase (1974) , Web of Science, and Scopus databases for eligible studies from inception until November 2016. Filters were not used for the type of study or language, but only studies in human populations were included. In collaboration with the subject librarian (R.F.) at the Medical Library, Queen's University Belfast, the following terms and keywords were used: (a) 'Metformin or Glucophage'; (b) 'Pre-eclampsia or Pre-eclamp* or Preeclampsia or Preeclamp*'; and (c) 'Gestational hypertension or Pregnancyinduced hypertension'. Combinations of (a) AND (b) or (a) AND (c) were also used.
Study inclusion criteria
Only those studies that met all of the following criteria were considered: original study; RCT or prospective observational study/cohort study; inclusion of women who took metformin before pregnancy and/or during pregnancy; and inclusion of women who were followed throughout the pregnancy with pregnancy outcomes recorded. We only included studies in which pre-eclampsia was diagnosed based on the following criteria, as per American College of Obstetricians and Gynaecologists guidelines [1] : at least two consecutive blood pressure measures ≥140/90 mm Hg with proteinuria (≥0.3 g per 24 h or 2 + on dipstick testing), and documented onset after gestational week 20. Three studies were included that defined and diagnosed preeclampsia in women with new-onset hypertension in the absence of proteinuria but with one of the following: haematological involvement; liver involvement; neurological involvement; pulmonary oedema; foetal growth restriction; or placental abruption [13, 14, 22] .
Data extraction
The following data were extracted from the 18 studies selected (Table 1) : study characteristics (author, year of publication, country), population characteristics (age, BMI at enrolment, blood pressure at baseline, weight change during pregnancy, glycaemic control), treatment design (number of women on metformin or placebo/insulin, dose of metformin and duration of treatment) and outcomes (primary and secondary outcomes).
What's new?
• This study shows that metformin with and without insulin treatment is associated with a lower incidence of pre-eclampsia than insulin treatment alone in women with gestational diabetes mellitus or Type 2 diabetes; this is probably linked to reduced weight gain during pregnancy in those taking metformin.
• In other high-risk pregnancies where hypoglycaemic agents are not essential, metformin does not appear to be beneficial.
• Clinical guidelines, which recommend insulin as the first-line treatment in pregnancies complicated by diabetes, should be reviewed in light of these findings, and adequately designed randomized controlled trials with pre-eclampsia as a primary outcome carried out.
ª 2017 Diabetes UK (11) whether benefit is worth the harm and costs (RCTs) or whether the results fit other available evidence (cohort studies). The scores were compared between the two reviewers (A.A. and L.M.) and any differences were discussed to reach a consensus. The quality scores based on the CASP tool assessment for each study are listed in the Table S1 . Some RCTs scored lower in categories such as appropriate blinding (metformin vs insulin RCTs), the size effect and precision of the results, ability to apply results locally (RCTs) and primary and secondary outcomes.
The main categories where the cohort studies scored lower included: recruitment; acceptable controls; adjustment for confounding factors; and application of the results to the local community. The risk of bias assessment was only possible for RCTs. We used REVMAN 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) software which automatically generated a panel representing overall risk of bias for each study based on random sequence generation, allocation and concealment, blinding of participants and personnel, blinding outcome assessment, incomplete outcome data, selective reporting and other bias.
Data synthesis and analysis
Risk ratios (RRs) and accompanying standard errors were extracted from each study in relation to pre-eclampsia. In each, unadjusted estimates were recorded. A meta-analysis was performed to obtain pooled RRs for pre-eclampsia in pregnant women treated with metformin compared with placebo or insulin using RCTs only; for cohort studies metformin treatment was compared with control (diet control or healthy pregnancies) or insulin. Four separate analyses were, therefore, performed to compare effects of metformin vs. placebo/control and metformin vs. insulin, in RCTs only or cohort studies only, on the incidence of preeclampsia. In our analyses, women taking metformin who subsequently needed insulin to maintain good glycaemic control during the course of the pregnancy were included in the metformin arm. Clinical outcomes in RCTs that have shown a positive association with pre-eclampsia (e.g. mean fasting blood glucose from enrolment to delivery, HbA 1c at 36-37 weeks, GDM incidence, and mean weight gain from enrolment to delivery), where available, were used to perform a meta-analysis to obtain pooled standard mean differences in pregnant women treated with metformin compared with placebo or insulin. A meta-analysis was also performed to examine if pooled standard mean differences in age and BMI were different in pregnant women treated with metformin compared with control in cohort studies. Random effects models were used to combine estimates to account for any heterogeneity present in the studies. Heterogeneity among studies was tested using a chi-squared test and measured using the I 2 statistic. REVMAN 5.3
software and STATA 12 software (StataCorp LP, College Station, TX) were used to carry out these analyses. Either RCTs or cohort studies were included in the meta-analyses. Publication bias was assessed by funnel plots representing the log RR against the standard error [23].
Results
Study selection
As shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart ( Fig. 1) , the database search and literature screening yielded 364 studies. After removing duplicates, two reviewers (A.A. and L.M.) screened the titles and abstracts of the remaining 321 articles. After initial screening, 293 articles were excluded because they did not meet the inclusion criteria and were outside of the scope of the review. Two reviewers (A.A. and L.M.) independently assessed the full text of the remaining 28 articles. Three were excluded because they repeated findings from another included study. Three studies did not clearly define pre-eclampsia. Three studies were excluded because their corresponding authors did not respond to requests for clarification or additional information. This yielded a total of 19 studies. The selected studies compared women receiving metformin treatment with healthy women or women on a healthy diet (n = 5) [22, [24] [25] [26] [27] , placebo (n = 4) [14, 16, 28, 29] or insulin (n = 11) [13, 15, 22, [30] [31] [32] [33] [34] [35] [36] [37] (one study, with three treatment arms, was included in both the metformin vs. control and the metformin vs. insulin analyses [22] ). The participants of the selected studies included women with GDM (n = 7) [13, 15, 22, [32] [33] [34] , women with Type 2 diabetes (n = 1) [31] , women with both
Total number of studies identified Medline n = 22 Embase n = 15 Web of science n = 45
Scopus n = 270 From bibliography n = 12
Duplicates removed n = 43
Potentially relevant studies identified n = 321
Studies not meeting inclusion criteria based on content of title and abstract n=293
Full-text studies assessed for eligibility n = 28
Poorly defined outcome n = 3 Duplicate studies n = 3 No desirable outcome n = 3
Studies included in systematic review n = 19
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines flow diagram.
GDM and Type 2 diabetes (n = 3) [34] [35] [36] , women with PCOS (n = 6) [16, [24] [25] [26] [27] 29] and obese women (n = 2) [14, 28] .
Study characteristics
The characteristics of the 19 selected studies are described in detail in Table 1 . Fourteen RCTs [13] [14] [15] [16] [27] [28] [29] [30] [31] [32] [33] [34] [35] 37] and five cohort studies [22, [24] [25] [26] 36] were included. The baseline age range for all the women (n = 3374) was 16-46 years, but most of the studies included women aged <35 years. The majority of the women were overweight (BMI 25-30 kg/m², 35%) or obese (BMI >30 kg/m², 64%); only 1% had a normal BMI at enrolment. Metformin treatment was initiated before pregnancy in three out of 19 studies [24] [25] [26] , all in women with PCOS, in whom the aim was to enhance fertility. Pre-eclampsia was reported as a primary outcome only in four studies [16, 24, 26, 36] and as a secondary outcome in 15 studies [13] [14] [15] 22, 25, [27] [28] [29] [30] [31] [32] [33] [34] [35] 37] . All studies were published in or after the year 2000. The studies were carried out worldwide: Australia (n = 1); Brazil (n = 1); Denmark (n = 1); Finland (n = 2); Ghana (n = 1); Italy (n = 1), Iran (n = 2); New Zealand (n = 2); Norway (n = 2); Pakistan (n = 2); UK (n = 2); USA (n = 3).
Meta-analysis of pre-eclampsia incidence
A meta-analysis of five RCTs [14, 16, [27] [28] [29] comparing the effects of metformin vs. placebo included 1220 pregnant women (611 in the metformin group, and 609 in the placebo group; Fig. 2a ). There was no significant difference in the incidence of pre-eclampsia between these two groups; the RR in the treatment arm was 0.86 (95% CI 0.33-2.26; P = 0.76).
There was a significant heterogeneity among these five studies (I² = 66%, P = 0.02). When the four prospective observational cohort studies [22, [24] [25] [26] were combined in a metaanalysis, the RR was 1.21 (95% CI 0.56-2.61; P = 0.62), also demonstrating no difference between the metformin and the control group (diet or no intervention) in terms of preeclampsia incidence. Heterogeneity was acceptable at 30%. Three out of four cohort studies, however, compared a group of women with PCOS taking metformin with a group of healthy pregnant women, and found a similar pre-eclampsia incidence in the the two groups, suggesting possible benefit of metformin in pregnant women with PCOS [24] [25] [26] . When the effects of metformin were compared with those of insulin, after exclusion of one RCT [37] in which a high risk of bias was discovered (REVMAN 5.3 risk of bias assessment), a meta-analysis of eight RCTs [13, 15, [30] [31] [32] [33] [34] [35] was performed. This meta-analysis included 1674 pregnant women (838 on metformin treatment and 836 on insulin treatment) and the results showed a reduction in preeclampsia incidence associated with metformin (RR 0.68, 95% CI 0.48-0.95; P = 0.02; Fig. 2c ). There was no heterogeneity among these studies in relation to preeclampsia incidence (I² = 0%). A meta-analysis of two cohort studies [22, 36] included 956 pregnanies, 515 in the metformin group and 441 in the insulin group, and found no difference in the incidence of pre-eclampsia between the groups (RR 1.61, 95% CI 0.42-6.12; P = 0.49; Fig. 2d) , however, the results are difficult to interpret because of the small number of studies included and significant heterogeneity between the studies of 79%. All meta-analyses performed, the associated forest and funnel plots, and the risk of bias assessment for RCTs are summarized in Fig. 2 .
Meta-analyses of clinical characteristics associated with preeclampsia Advanced age, BMI, GDM, glycaemic control in women with diabetes and weight gain during pregnancy have all been strongly and independently associated with preeclampsia [2, 9, 17, [38] [39] [40] and, for this reason, we evaluated if incidence of GDM or glycaemic control and weight gain status differed between metformin and control or insulin groups. We also explored whether baseline BMI and age differed between groups in cohort studies.
Metformin vs. control
As the randomization process in RCTs ensures an even distribution of clinical characteristsics between intervention and control groups, the baseline differences in BMI and age in metfomin vs. control groups was examined in cohort studies only. A meta-analysis of pooled BMI means from three cohort studies [24] [25] [26] showed a significant difference between metformin and control groups (P < 0.001; Fig. 3a) and no heterogeneity amongst studies included. This was not surprising as all of these studies used a healthy pregnancy cohort as the control group, suggesting that BMI was a confounding factor in this analysis. When the same analysis was carried out for age in the three cohort studies [24] [25] [26] , no difference was observed between the metformin and the control group (P = 0.28; Fig. 3b ).
With regard to the incidence of dysglycaemia in women with PCOS and obese women, no difference was found in the number of GDM cases between the metformin and placebo groups in RCTs (n = 522 in metformin group and n = 499 in placebo group; RR 0.89, 95% CI 0.69-1.16, P = 0.4; Fig. 4a) , or between the metformin and control group in cohort studies (n = 714 in metformin group and n = 888 in control group; RR 0.80, 95% CI 0.39-1.64, P = 0.54; Fig. 4b) . Heterogeneity among the studies was 0% in the RCTs and 67% in the cohort studies.
Mean weight gain from enrolment to delivery was reported in three RCTs [14, 16, 28] comparing metformin with placebo, and meta-analysis of these data indicated that weight gain was lower in the metformin than in the control groups (P = 0.05; Fig. 4c) ; however, heterogeneity among the studies was very high (I 2 = 93%) so it is difficult to interpret this finding. Heterogeneity: Tau In relation to glycaemic control we investigated differences in mean fasting blood glucose and HbA 1c levels between metformin and insulin groups from enrolment until weeks 36-37. The mean fasting blood glucose level was recorded in six studies [13, 15, 31, [33] [34] [35] , while HbA 1c level was recorded in five studies [13, 15, 30, 33, 34] . There were no significant differences between metformin and insulin treatment groups in relation to fasting blood glucose (P = 0.36; Fig. 5a ) and HbA 1c (P = 0.73, mmol/mol; Fig. 5b ; P = 0.75, %; Fig. S1 ). The percentage of women in the metfomin group who subsequently received insulin ranged from 14% to 85% (Table S2 ). The two biggest studies reported that, between them, 33% of women in the metformin groups received supplementary insulin [13, 30] . There was substantial variation in the way that weight gain was recorded, so that mean weight gain could only be included from four out of seven studies, which included metformin and insulin groups, in the meta-analysis [13, 30, 33, 34] . These studies recorded weight gain from enrolment to delivery; in three studies women were enrolled from approximately 20-34 weeks' gestation [13, 30, 33] , whereas one study enrolled women from 10-22 weeks' gestation [34] . A meta-analysis of pooled mean weight gain from entry to delivery showed that women on metformin gained less weight during pregnancy than women on insulin (P = 0.004; Fig. 5c ).
High heterogeneity was reported among the studies in relation to the following clinical variables that were included in the meta-analyses: fasting blood glucose (I 2 = 66%), HbA 1c (I 2 = 78%) and mean weight gain (I 2 = 78%).
Discussion
This is the first systematic review and meta-analysis to focus on the incidence of pre-eclampsia in pregnant women taking metformin vs. placebo or insulin, and elucidates potential clinical mechanisms in insulin-resistant women. In the present review, we analysed and critically appraised both prospective observational clinical studies and RCTs that compared the use of metformin treatment with placebo/ control or insulin treatment in pregnant women with insulinresistant disorders such as PCOS, obesity, Type 2 diabetes and GDM. Such women are at higher risk of developing complications of pregnancy including pre-eclampsia. We performed meta-analyses separately for cohort studies and RCTs. We also carried out two separate analyses comparing results for metformin vs. placebo/control and metformin vs. insulin. 
FIGURE 3
Meta-analyses of BMI and age in metformin vs. placebo treatment group. (a) Meta-analysis of cohort studies comparing BMI in a metformin and a control group. (b) Meta-analysis of cohort studies comparing age in a metformin and a control group. Random effects models were used to combine estimates and analyses were carried out using REVMAN 5.3 software; standard mean difference was calculated, and the overall effect was measured using Z-test with P values < 0.05 taken to indicate statistical significance. Heterogeneity was calculated using a chi-squared test and measured by the I 2 statistic. Random effects models were used to combine estimates and analyses were carried out using REVMAN 5.3 software. Risk ratio was calculated, and the overall effect was measured using Z-test with P values <0.05 taken to indicate statistical significance. Heterogeneity was calculated using a chi-squared test and measured by the I 2 statistic.
Metformin vs. placebo/control
The results obtained suggest that there is no difference in the incidence of pre-eclampsia between women given metformin and women given placebo or a control group. We recognize that in the RCTs, the presence of a placebo arm implies that a hypoglycaemic agent was not clinically mandated (e.g. in women with PCOS and obese women), and therefore eligible participants were likely to have had fewer risk factors than those requiring randomization to metformin or insulin (the cohorts with Type 2 diabetes and GDM). Limitations of some studies included comparison of metformin-treated women with PCOS with a healthy pregnant control group [24] [25] [26] . This was reflected in the meta-analysis of clinical characteristics which found BMI to be higher in participants on metformin than in the control group in the cohort study analysis, and hence is likely to be a confounding factor in relation to risk of pre-eclampsia. Another limitation was that pre-eclampsia was the primary outcome in only four of nine studies: three observational [24, 26, 36] and one RCT [16] . In addition, the heterogeneity among metformin vs. placebo RCTs was high, therefore the results are difficult to interpret. Only two studies comparing metformin with placebo recruited obese women with a BMI >30 kg/m 2 and without diabetes, and, although of similar size, these two studies reached opposite conclusions [14, 28] . In one, the number of women with pre-eclampsia was significantly lower in the metformin group (odds ratio 0.24; P = 0.001) [14] , whereas in the other, although statistical significance was not reached, a higher incidence of pre-eclampsia was reported in metformin group (odds ratio 2.39; P = 0.21) [28] . The baseline characteristics of the participants in both studies were very similar except that one study included only white women [28] , whereas the other study included all racial groups and therefore was more representative of the general population in the UK [14] . In the latter study, a lower incidence of pre-eclampsia was observed in the metformin group compared with the placebo group. In both, pre-eclampsia was recorded as a secondary outcome. Random effects models were used to combine estimates and analyses were carried out using RevMan 5.3 software. Standard mean difference or risk ratio was calculated, and the overall effect was measured using Z-test with P values < 0.05 taken to indicate statistical significance. Heterogeneity was calculated using a chi-squared test and measured by the I 2 statistic.
Furthermore, the incidence of GDM did not differ between metformin and placebo/control groups whether RCTs or cohort studies were examined, suggesting that metformin did not have a significant effect on preventing GDM. Women who develop GDM have a higher incidence of pre-eclampsia [17] ; therefore, it is possible that metformin in these cohorts of women was unable to prevent GDM (Fig. 4a,b) , and, as a result, no difference in pre-eclampsia incidence was observed. However, weight gain, which was only reported in three RCTs [14, 16, 28] , was borderline significant in favour of metformin being associated with lower weight gain during pregnancy. The effect of metformin on weight gain, therefore, appears to be more pronounced in people with diabetes than in those without diabetes.
Despite the fact that metformin activates the AMPK pathway, an effect that has been shown to inhibit processes directly relevant to the pathogenesis of pre-eclampsia, such as irregular angiogenesis, endothelial dysfunction and inappropriate placental development [19] [20] [21] , it was not found to be superior to placebo/control in reducing the incidence of pre-eclampsia in the present meta-analysis. Interestingly, Vanky et al. [29] reported that severe pregnancy complications, which included pre-term delivery before 32 weeks, severe pre-eclampsia or serious post-partum events, occurred only in the placebo group (placebo, 7/22 participants vs. metformin, 0/18 participants; P = 0.01). The effect of metformin vs. placebo on severe pre-eclampsia should, therefore, be investigated in the future.
Interestingly, clinical studies which assessed cardiovascular effects of metformin in people without Type 2 diabetes, showed little or no effect on the markers of cardiovascular disease [41] ; the Diabetes Prevention Programme also demonstrated no beneficial effect of metformin in reducing the incidence of hypertension in people without Type 2 diabetes [42] . Conversely, in people with Type 2 diabetes in the UK Prospective Diabetes Study [43] , the cardiovascular benefits of metformin were well substantiated. This differential effect of metformin in people with vs. without diabetes could also be relevant to pre-eclampsia, a disease of the cardiovascular system, characterized by hypertension and proteinuria. 
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Mean weight gain after entry (kg; metformin vs. insulin; RCTs) Ainuddin Random effects models were used to combine estimates and analyses were carried out using REVMAN 5.3 software. S standard mean difference was calculated and the overall effect was measured using Z-test with P values < 0.05 taken to indicate statistical significance. Heterogeneity was calculated using a chi-squared test and measured by the I 2 statistic.
The comparison between metformin and insulin demonstrated a reduction in RR of pre-eclampsia in favour of metformin in the meta-analysis of RCTs. This result is convincing, considering there was no heterogeneity among the studies. Nevertheless, in these studies, a common weakness was that neither the investigators nor the participants were blinded because of the different routes of administration of the study drugs. Glycaemic control was similar between groups at the start or throughout the trial; weight gain after enrolment was significantly lower in the metformin group. Weight gain has been linked to an increased risk of preeclampsia [44] . Other possibilities for bias included a high risk of random sequence generation, and allocation concealment which was present in two studies [15, 31] . In all the studies taken together, an average of 45% of the women in the metformin group needed supplementary insulin (Table S2 ). When we carried out a meta-analysis comparing metformin alone vs. insulin alone, which included six RCTs, the incidence of pre-eclampsia remained lower in the metformin group but significance was lost (RR 0.73, 95% CI 0.40-1.34; P = 0.31; Fig. S2 ). Administration of aspirin was not reported in any of the studies included. Nevertheless, most of these studies are relatively small, and therefore there may still be justification for a larger study with pre-eclampsia as a primary outcome to address the question definitively.
Overall, even though metformin AE insulin vs. insulin alone was associated with a lower risk of pre-eclampsia, it is unclear whether this was because insulin itself might increase the risk of pre-eclampsia, perhaps in part by causing weight gain, or whether this is a beneficial effect of metformin. A large population-based registry study in Finland [45] compared pregnancy outcomes in women with GDM who were aged <35 years or >35 years vs. women without GDM in the same age groups. Women with GDM were treated with diet or insulin. We calculated the RRs for pre-eclampsia, based on the data presented in the paper, in women with GDM treated with diet and in those treated with insulin in both age groups. This showed that, in women with GDM who were aged <35 years, insulin (238/2845) increased the risk of preeclampsia (RR 1.19; CI 1.04-1.36; P = 0.0092) compared with diet (1161/19422); no difference was found in the prevalence of pre-eclampsia between the diet and insulin groups in women with GDM who were aged >35 years. Most of the women (>90%) in our meta-analysis were aged <35 years, which suggests that metformin may only have a marginal effect on preventing the risk of pre-eclampsia; however, it is still a better option than insulin alone in terms of the risk of pre-eclampsia and possibly other pregnancy complications. Further trials are needed to explore the incidence of pre-eclampsia in insulin and diet intervention groups. Prospective studies comparing insulin treatment with diet in women with GDM or Type 2 diabetes might be able to address this question. It is possible that metformin could have advantages over insulin in pregnant women who require a hypoglycaemic agent; these advantages could be even more pronounced in women aged >35 years according to the findings of Lamminp€ a€ a et al. [45] . Nevertheless, these women might still need insulin supplementation in the later stages of pregnancy to control hyperglycaemia. In women on metformin AE insulin, the weight gain is less than in women on insulin alone, and it is likely that the dose of insulin may be lower when metformin is used; both factors are potentially beneficial in relation to pre-eclampsia. By contrast, in the studies comparing metformin with placebo or no treatment, hypoglycaemic intervention was either optional or not needed; in these women, the data showed no evidence in favour of metformin for reducing the risk of pre-eclampsia. It is important to explore further the effects of metformin vs. placebo/control on the early or severe type of pre-eclampsia characterized by onset of pre-eclampsia before 34 weeks' gestation or blood pressure ≥160/110 mmHg. It is possible, as suggested by Myatt et al. [46] , that there are different phenotypes of pre-eclampsia and that this is the reason why large clinical studies have failed to validate findings observed in the smaller studies [46] ; therefore, correct stratification of high-risk women according to age, presence of diabetes, blood pressure or BMI is important and this could determine the most appropriate preventative treatment. Also, women with GDM or Type 2 diabetes during pregnancy are frequently given, or swapped to, insulin instead of metformin. These women are at high risk of pre-eclampsia; it is possible, based on this review, and other published data, that metformin AE supplementary insulin would be a better option during pregnancy in these women than insulin alone.
Clearly, in the present systematic review we could not include (and did not find) any studies of pregnancy in women with Type 1 diabetes. These women also have a four-fold increased risk of developing pre-eclampsia, similarly to women with Type 2 diabetes [9, 10] . Considering that metformin in addition to insulin appears beneficial compared with insulin alone, future randomized double-blind placebo-controlled trials investigating the ability of metformin, in addition to insulin, in prevention of pre-eclampsia in pregnant women with Type 1 diabetes could be valuable. In the present analysis, with pre-eclampsia rates of 20% in the insulin group and 14% in the metformin group (estimated based on a 30% reduction in the metformin group observed in this meta-analysis), 650 women with pre-gestational Type 1 diabetes would need to be recruited in each group to have >80% power to detect this difference as statistically significant.
In conclusion, in pregnant women requiring hypoglycaemic treatment, metformin alone or metformin in combination with insulin is associated with less weight gain and a lower incidence of pre-eclampsia than insulin alone. This suggests that metformin AE supplementary insulin treatment is linked to more favourable pregnancy outcomes, such as a reduced risk of pre-eclampsia, than insulin alone. This effect is likely to be age-dependent and associated with reduced
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